Physician profile
Marshall Meier
NPI 1205368925
$1,836.21
in general payments reported to CMS, 2019-2025
13 companies · $31.03 in 2025
The $31.03 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.05 · 2022: $925 · 2023: $706 · 2024: $92.18 · 2025: $31.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $597.05 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $397.05 | 2022-2024 | Eliquis, Camzyos |
| Shionogi INC | $206.80 | 2022-2024 | Fetroja |
| Merck Sharp & Dohme LLC | $132.73 | 2022-2025 | Dificid, Zerbaxa, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.07 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $85.78 | 2022-2023 | Lokelma |
| Vifor Pharma, INC. | $79.88 | 2022-2023 | Veltassa |
| Csl Behring | $78.64 | 2023 | Kcentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.90 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $38.41 | 2022-2023 | Ultomiris |
| Ferring Pharmaceuticals INC. | $37.78 | 2023 | Rebyota |
| Gilead Sciences, INC. | $23.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.